Hypercalcaemia in infancy; a presenting feature of spinal muscular atrophy

K Khawaja1, W T Houlsby, S Watson

  • 1Department of Paediatrics, Royal Victoria Infirmary, Newcastle upon Tyne NE1 4LP, UK.

Insights

A 10-month-old girl with constipation experienced hypercalcemia and nephrocalcinosis. This case highlights spinal muscular atrophy as a potential cause of altered bone turnover and hypercalcemia in infants.

Area of Science:

  • Pediatric Endocrinology
  • Neuromuscular Disorders
  • Metabolic Bone Disease

Background:

  • Constipation is a common pediatric issue, but persistent hypercalcemia, hypercalciuria, and nephrocalcinosis in infants warrant thorough investigation.
  • Early motor delay and hypotonia can be associated with chronic hypercalcemia, but alternative diagnoses should be considered if symptoms persist despite metabolic correction.

Observation:

  • A 10-month-old female infant presented with early-onset constipation, hypercalcemia, hypercalciuria, and nephrocalcinosis.
  • Despite achieving normocalcemia through dietary calcium restriction, the infant's motor delay and hypotonia did not resolve, prompting further etiological exploration.

Findings:

  • The infant was diagnosed with spinal muscular atrophy type 2, a progressive neuromuscular disorder.
  • The study suggests a potential link between reduced muscular activity in spinal muscular atrophy and altered bone turnover, leading to hypercalcemia and hypercalciuria.

Implications:

  • This case underscores the importance of considering neuromuscular conditions in the differential diagnosis of pediatric hypercalcemia, particularly when associated with motor impairments.
  • Altered bone metabolism secondary to immobility may contribute to hypercalcemic syndromes, necessitating a multidisciplinary approach for accurate diagnosis and management in pediatric patients.
  • Early identification of spinal muscular atrophy is crucial for timely intervention and management of associated metabolic complications.

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...